1 Design , Synthesis , in Vitro and in Vivo Biological Evaluation of 2-Amino-3-Aroylbenzo [ b ] furan Derivatives as Highly Potent Tubulin Polymerization Inhibitors

No abstract is available for this paper.

• Publication year

  2022

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Design and Development of Cost-Effective Child Surveillance System using Computer Vision Technology

  2022cited by this paper
• Colchicine-Binding Site Inhibitors from Chemistry to Clinic: A Review

  2020cited by this paper
• Molecular modeling study, synthesis and biological evaluation of combretastatin A-4 analogues as anticancer agents and tubulin inhibitors.

  2018cited by this paper
• Access to 1a,6b-Dihydro-1H-benzofuro[2,3-b]azirines and Benzofuran-2-amines via Visible Light Triggered Decomposition of α-Azidochalcones.

  2017cited by this paper
• Recent advances in combretastatin based derivatives and prodrugs as antimitotic agents.

  2017cited by this paper
• Caspase-9: structure, mechanisms and clinical application

  2017cited by this paper
• Development of combretastatins as potent tubulin polymerization inhibitors.

  2017cited by this paper
• Blocking Blood Flow to Solid Tumors by Destabilizing Tubulin: An Approach to Targeting Tumor Growth.

  2016cited by this paper
• The Novel Antitubulin Agent TR-764 Strongly Reduces Tumor Vasculature and Inhibits HIF-1α Activation

  2016influential reference
• Combretastatins: More Than Just Vascular Targeting Agents?

  2015cited by this paper
• The Molecular Biology of Spindle Assembly Checkpoint Signaling Dynamics.

  2015cited by this paper
• Control of microtubule organization and dynamics: two ends in the limelight

  2015cited by this paper
• Antimitotic drugs in the treatment of cancer

  2015cited by this paper
• Tubulins - the target for anticancer therapy.

  2015cited by this paper
• Design, syntheses, structure-activity relationships and docking studies of coumarin derivatives as novel selective ligands for the CB2 receptor.

  2015cited by this paper
• Design, synthesis, in vitro, and in vivo anticancer and antiangiogenic activity of novel 3-arylaminobenzofuran derivatives targeting the colchicine site on tubulin.

  2015cited by this paper
• Tubulin colchicine binding site inhibitors as vascular disrupting agents in clinical developments.

  2015cited by this paper
• The NOXA–MCL1–BIM axis defines lifespan on extended mitotic arrest

  2015cited by this paper
• Tubulin inhibitors: a patent review

  2014cited by this paper
• Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors

  2014cited by this paper
• The contribution of αβ-tubulin curvature to microtubule dynamics

  2014cited by this paper
• The tubulin code: Molecular components, readout mechanisms, and functions

  2014cited by this paper
• Synthesis, antimitotic and antivascular activity of 1-(3',4',5'-trimethoxybenzoyl)-3-arylamino-5-amino-1,2,4-triazoles.

  2014cited by this paper
• Old, new and emerging functions of caspases

  2014cited by this paper
• Synthesis and Biological Evaluation of Benzo[b]furans as Inhibitors of Tubulin Polymerization and Inducers of Apoptosis

  2014cited by this paper
• Vascular-disrupting agents in oncology

  2013cited by this paper
• Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy

  2013cited by this paper
• TR-644 a novel potent tubulin binding agent induces impairment of endothelial cells function and inhibits angiogenesis

  2013cited by this paper
• Critical role of anti-apoptotic Bcl-2 protein phosphorylation in mitotic death

  2013cited by this paper
• Long Pentraxin-3 Inhibits Epithelial–Mesenchymal Transition in Melanoma Cells

  2013cited by this paper
• Discovery and optimization of a series of 2-aryl-4-amino-5-(3',4',5'-trimethoxybenzoyl)thiazoles as novel anticancer agents.

  2012cited by this paper
• Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck.

  2012cited by this paper
• Phase I Trial of Combretastatin A4 Phosphate (CA4P) in Combination with Bevacizumab in Patients with Advanced Cancer

  2012cited by this paper
• New insights into the mechanisms of cytomotive actin and tubulin filaments.

  2011cited by this paper
• Discovery of 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties.

  2011cited by this paper
• Synthesis and Antitumor Molecular Mechanism of Agents Based on Amino 2‐(3′,4′,5′‐Trimethoxybenzoyl)benzo[b]furan: Inhibition of Tubulin and Induction of Apoptosis

  2011cited by this paper
• Synthesis of 2-(1-Phenylvinyl)benzofurans and 2-(1-Phenylvinyl)indoles as Antimitotic Agents by a Tandem Palladium-Assisted Coupling-Cyclization Reaction between 1-Phenylvinyl Iodides and ortho-Substituted Arylalkynes

  2011cited by this paper
• Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7

  2011cited by this paper
• Role of Cyclin B1/Cdc2 Up-Regulation in the Development of Mitotic Prometaphase Arrest in Human Breast Cancer Cells Treated with Nocodazole

  2011cited by this paper
• Microtubule-targeted agents: when mitochondria become essential to chemotherapy.

  2011cited by this paper
• BNC105: A Novel Tubulin Polymerization Inhibitor That Selectively Disrupts Tumor Vasculature and Displays Single-Agent Antitumor Efficacy

  2010cited by this paper
• AVE8062: a new combretastatin derivative vascular disrupting agent

  2009cited by this paper
• Synthesis and biological evaluation of 1-methyl-2-(3',4',5'-trimethoxybenzoyl)-3-aminoindoles as a new class of antimitotic agents and tubulin inhibitors.

  2008cited by this paper
• Synthesis and biological evaluation of 2-(3',4',5'-trimethoxybenzoyl)-3-N,N-dimethylamino benzo[b]furan derivatives as inhibitors of tubulin polymerization.

  2008cited by this paper
• Evaluation of antimitotic agents by quantitative comparisons of their effects on the polymerization of purified tubulin

  2007cited by this paper
• Polychromatic Analysis of Mitochondrial Membrane Potential Using JC‐1

  2007influential reference
• Synthesis and biological evaluation of 2- and 3-aminobenzo[b]thiophene derivatives as antimitotic agents and inhibitors of tubulin polymerization.

  2007cited by this paper
• Spindle checkpoint function and cellular sensitivity to antimitotic drugs

  2006cited by this paper
• The discovery and development of the combretastatins

  2005cited by this paper
• One-pot synthesis of benzo[b]furan and indole inhibitors of tubulin polymerization.

  2002influential reference
• Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: An update

  2002cited by this paper
• Synthesis and Characterization of

  2001cited by this paper
• Rare-Earth-Containing Magnetic Liquid Crystals

  2000cited by this paper
• Structure-activity analysis of the interaction of curacin A, the potent colchicine site antimitotic agent, with tubulin and effects of analogs on the growth of MCF-7 breast cancer cells.

  1998cited by this paper
• Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin.

  1989cited by this paper
• Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4

  1989cited by this paper
• Statistical Analysis of

  1954cited by this paper

• No citing papers are available for this paper.